GlassScriptPhysician profile
Bradley D Rasmussen
NPI 1942230925
$6,390.64
in general payments reported to CMS, 2019-2025
30 companies · $1,020 in 2025
The $1,020 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $173 · 2020: $76.84 · 2021: $201 · 2022: $1,445 · 2023: $1,717 · 2024: $1,758 · 2025: $1,020.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,423 · Education: $72.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,423.15 |
| Education | $72.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,402.07 | 2020-2025 | |
| Janssen Biotech, INC. | $783.43 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Amgen INC. | $735.24 | 2021-2025 | Otezla, Otezla, Enbrel |
| Lilly USA, LLC | $601.38 | 2020-2025 | Olumiant, Taltz, Ebglyss |
| Sun Pharmaceutical Industries INC. | $480.08 | 2019-2025 | Odomzo, Blu-U, Ilumya |
| E.R. Squibb & Sons, L.L.C. | $414.96 | 2022-2025 | Sotyktu |
| Ucb, INC. | $358.38 | 2024-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $259.03 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $251.29 | 2021-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $172.74 | 2021-2024 | |
| Janssen Scientific Affairs, LLC | $109.18 | 2022 | |
| Dermavant Sciences, INC. | $100.38 | 2023-2024 | Vtama |
| Pfizer INC. | $89.39 | 2019-2025 | |
| Leo Pharma INC. | $89.34 | 2022-2025 | Adbry |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.94 | 2023-2024 | Spevigo |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $55.16 | 2023-2025 | Opzelura |
| Galderma Laboratories, L.P. | $51.83 | 2020-2022 | |
| Almirall LLC | $50.72 | 2023 | Klisyri |
| Smith+Nephew, INC. | $45.62 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $44.49 | 2023-2024 | Siliq, Targretin, Jublia |
| Arcutis Biotherapeutics, INC. | $37.52 | 2023-2025 | Zoryve |
| Takeda Pharmaceuticals U.S.A., INC. | $31.17 | 2025 | |
| Epi Health, LLC | $23.01 | 2022 | |
| Journey Medical Corporation | $22.03 | 2025 | |
| Solta Medical, A Division of Bausch Health US, LLC | $21.01 | 2025 | |
| Springworks Therapeutics, INC. | $18.48 | 2025 | Gomekli |
| Organon LLC | $18.35 | 2025 | Vtama |
| Dusa Pharmaceuticals, INC. | $17.53 | 2019 | |
| Fidia Pharma USA INC. | $16.14 | 2024 | |
| Acera Surgical, INC. | $13.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Rasmussen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.